Drug Interaction Study of ASC42 With Atorvastatin
Condition(s):HealthyLast Updated:October 17, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):HealthyLast Updated:October 17, 2022Recruiting
Condition(s):Alagille Syndrome; Atorvastatin; XanthomaLast Updated:October 17, 2023Recruiting
Condition(s):Efficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year; Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year; All-cause Mortality Events (Within 1 Year); Incident Ischemic Stroke Events (Within 1 Year); New Hemorrhagic Stroke Events (Within 1 Year); New Stent Thrombosis Events (Within 1 Year); New Symptomatic Stenosis Events (Within 1 Year); Occurrence of In-stent Stenosis 12th ±1 Month Annual Angiographic Follow-up; Degree of In-stent Stenosis (as Measured by WASID Method) at the 12th ±1 Month Annual Angiographic Follow-up; Target Aneurysm Embolization Rate at 12±1 Month Annual Angiographic Follow-up (Raymond and OKM Classification)Last Updated:March 13, 2024Not yet recruiting
Condition(s):HealthyLast Updated:March 27, 2020Unknown status
Condition(s):Acute Myocardial Infarction; Glucose Metabolism DisordersLast Updated:May 12, 2022Recruiting
Condition(s):Lynch SyndromeLast Updated:April 7, 2022Recruiting
Condition(s):Atorvastatin Antihypertensive EffectLast Updated:January 10, 2023Completed
Condition(s):HealthyLast Updated:December 1, 2020Completed
Condition(s):Carotid Artery StenosisLast Updated:April 9, 2020Unknown status
Condition(s):HealthyLast Updated:December 30, 2016Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.